NPCEHealthcare · Medical DevicesThe 9 Wall Street analysts covering NeuroPace, Inc. hold a median 12-month price target of $20 — +37.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 93 of 100 as at 14 Sept 2026 — among the strongest tenth. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores NeuroPace, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Momentum (83): The shares have been drifting up relative to others.
Value (59): The shares cost a lot relative to the profits and assets behind them.
Size (53): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on NPCE, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +37.1% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 29 July 2026 | HC Wainwright & Co. | Reiterates | Buy | $20 |
| 23 July 2026 | Mizuho | Initiates | Outperform | $22 |
| 15 May 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 15 May 2026 | HC Wainwright & Co. | Maintains | Buy | $19 → $20 |
| 27 Jan 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 16 Dec 2025 | UBS | Maintains | Buy | — |
| 10 Dec 2025 | JP Morgan | Maintains | Overweight | — |
| 5 Nov 2025 | JP Morgan | Maintains | Overweight | — |
| 5 Nov 2025 | Wells Fargo | Maintains | Overweight | — |
| 13 Aug 2025 | Wells Fargo | Maintains | Overweight | — |
| 28 May 2025 | HC Wainwright & Co. | Initiates | Buy | — |
| 14 May 2025 | Cantor Fitzgerald | Reiterates | Overweight | — |
| 14 May 2025 | JP Morgan | Maintains | Overweight | — |
| 14 Apr 2025 | Cantor Fitzgerald | Maintains | Overweight | — |
| 5 Mar 2025 | Cantor Fitzgerald | Maintains | Overweight | — |
| 30 Jan 2025 | Wells Fargo | Maintains | Overweight | — |
| 21 Jan 2025 | UBS | Initiates | Buy | — |
| 17 Dec 2024 | JP Morgan | Maintains | Overweight | — |
| 13 Nov 2024 | Wells Fargo | Maintains | Overweight | — |
| 14 Aug 2024 | Cantor Fitzgerald | Reiterates | Overweight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. NPCE appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 14 Sept 2026, NeuroPace, Inc. returned +48.0% against +17.0% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 96% of US stocks
Cheaper than 27% of US stocks
Cheaper than 2% of US stocks
Cheaper than 94% of US stocks
Higher than 66% of US stocks
Higher than 33% of US stocks
Higher than 93% of US stocks
Higher than 21% of US stocks
Higher than 16% of US stocks
Higher than 13% of US stocks
Higher than 29% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
NeuroPace, Inc. has a market value of $481.9M and an enterprise value of $500.1M.
Revenue in the twelve months to 30 June 2026: $98.8M. The latest quarter grew 17.1% year on year.
Net income over the same four quarters: −$19.1M, a −19.3% net margin.
Diluted earnings per share, trailing twelve months: $−0.57.
Free cash flow in the twelve months to 30 June 2026: −$11.6M.
NeuroPace, Inc. spent $0.0 on share buybacks in the twelve months to 30 June 2026.
Trailing P/E: −21.3×; forward P/E: −63.9× — the forward figure prices analyst consensus estimates, not reported earnings.
NeuroPace, Inc. employs 220 people — $449K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own NeuroPace, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
NeuroPace reported earnings about 30 days ago, and the article examines what may come next for the stock. The piece notes the company's shares have slipped 0.4% since the last earnings report.
Why it matters — NeuroPace watchers would care because the article provides a post-earnings update on the company's recent stock performance and outlook following its latest results.
Zacks Investment Research published a note recommending that investors retain NeuroPace stock for now, highlighting that RNS adoption, reimbursement gains, referral expansion, and AI tools support growth, while IGE delays and higher spending pressure profitability.
Why it matters — The note outlines both the growth drivers and profitability headwinds facing NeuroPace, giving watchers a balanced view of the company's current outlook.
NeuroPace, Inc. announced that its management team will participate in the 2026 Cantor Global Healthcare Conference, including a fireside chat on Wednesday, September 9 at 10:55am EDT and one-on-one meetings with investors during the conference.
Why it matters — The conference participation gives a NPCE watcher insight into the company's investor engagement and an opportunity to hear management discuss the business directly.
NeuroPace announced that its management team will participate in the Wells Fargo 21st Annual Healthcare Conference. The team will take part in a fireside chat on Tuesday, September 8 at 8:00am EDT and host one-on-one meetings with investors during the event.
Why it matters — The conference participation gives NeuroPace's management a public platform to discuss the company and engage directly with investors.
NeuroPace's IGE expansion is facing a regulatory delay, with the company working through the FDA review process. Attention is shifting to rising adoption of its RNS technology in the meantime.
Why it matters — A delay in the IGE expansion affects a key growth avenue for NeuroPace, so investors following NPCE would track how the FDA review progresses and how RNS adoption performs.
The 9 Wall Street analysts covering NeuroPace, Inc. have a median 12-month price target of $20, with estimates ranging from $18 to $22. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 9 analysts covering NeuroPace, Inc., 9 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks NeuroPace, Inc. 93 out of 100 across roughly 4,600 US stocks as at 14 Sept 2026. None of this is personal advice — it does not consider your circumstances.
As at 14 Sept 2026, NeuroPace, Inc. ranks 93 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (83 of 100).
No one can know that. What the data says: the median 12-month target from 9 analysts implies +37.1% from the last close, and Ticker Nerd's factor model ranks NeuroPace, Inc. 93 out of 100 as at 14 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering NeuroPace, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for NPCE are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $18 to $22 over the next 12 months.
NeuroPace, Inc. returned +48.0% over the 12 months to 14 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.
NeuroPace, Inc. is a medical device company focused on brain-responsive neuromodulation for people living with epilepsy.
The most recent item we track (Zacks Investment Research, 10 Sept 2026): "Why Is NeuroPace (NPCE) Down 0.4% Since Last Earnings Report?". NeuroPace reported earnings about 30 days ago, and the article examines what may come next for the stock. The piece notes the company's shares have slipped 0.4% since the last earnings report.
NeuroPace, Inc. is a medical device company focused on brain-responsive neuromodulation for people living with epilepsy. Its core RNS System is an implantable platform designed to detect abnormal brain activity and deliver targeted stimulation in response, helping physicians manage medically refractory focal epilepsy. The company’s product portfolio includes the RNS neurostimulator, depth and cortical strip leads, and accompanying patient monitoring and programming tools that support long-term therapy and remote clinical review. NeuroPace serves hospitals and epilepsy care centers, with its technology used in specialized neurology settings where individualized treatment is critical. The company operates in the neuromodulation and epilepsy treatment markets, where it plays a distinct role by combining continuous brain signal monitoring with responsive therapy in a single commercial system.
CEO Mr. Joel D. Becker · 220 employees · United States · https://www.neuropace.com
